chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sweating; Fever 102.8; Chills; Malaise; Myalgia; Arthralgia; Headache; This is a spontaneous report from a contactable nurse. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Medical history included depression, hashimoto's disease, acute kidney injury, catfish allergy, bivalved shellfish allergy and house dust mite allergy. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), olanzapine (ZYPREXA), desvenlafaxine succinate monohydrate (PRISTIQ), thyroid (ARMOUR THYROID) and hydroxyzine (ATARAX); all drugs started on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 24Feb2021 at 10:15 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. On 19Mar2021 at 12:00, the patient experienced fever 102.8 (unit unspecified), chills, sweating, malaise, myalgia, arthralgia and headache. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The patient received an unknown vaccine on 01Apr2021 for unknown indication. The clinical outcome of the events fever 102.8, chills, sweating, malaise, myalgia, arthralgia and headache were recovered on an unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
pt recvd Engerix-B 1APR92 & that evening exp numbness & tingling in the rt hand & arms; this lasted 4 hrs & was gone by the next morning; pt recvd dose 2 of vaxx 1MAY92 the next morning @ approx 4AM pt reported nausea, stiff neck & pain
About 12 hours after the vaccine, I woke up shivering, body and muscle aches, and severe headache.  These symptoms and fatigue persisted for about 30 hours.
Patient presented to the emergency room with acute chest pain in the sternal area and a troponin of 1.1.   EKG showed early repolarization, not concerning for ACS.   Her pain was classic for pericarditis in that it was worse when leaning back, nonexertional, and not accompanied by diaphoresis or nausea.  She was treated for presumed pericarditis with ibuprofen and colchicine.  Her troponin peaked at 4.6 and then downtrended.  Her chest pain resolved.  She was discharged with presumed pericarditis.
Severe diarrhea that lasted 6 weeks. Weight loss. Kidney stones. I have been battling diarrhea and stomach issues for ONE YEAR . I have had numerous tests: colonoscopy, CT scans and ultrasounds and bloodwork. I went to a new doctor Dr. with Health Associates at local hospital. They did a stool test that determined my pancreas isn't functioning properly. I have never had anything wrong with my pancreas before.
Pericarditis; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of PERICARDITIS (Pericarditis) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERICARDITIS (Pericarditis) (seriousness criterion medically significant). At the time of the report, PERICARDITIS (Pericarditis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. No treatment medication was provided.  Patient commented saying that while she may not have been evaluated for pericarditis as of yet, she has heard of others who have and ER nurses have also mentioned this to her.  Very limited information regarding the events has been provided at this time; Sender's Comments: Very limited information regarding the events has been provided at this time
pt became very pale & started to faint;placed w/head between legs for short time, then placed on floor & elevated legs;did not lose consciousness;pulse R80; lt w/mom in approx 15min;felt okay;
Elevated and elongated fever and chills weekly some weeks daily  since  June 2021 Lightheaded  Extreme fatigue  High pitched tingling in left ear  Abnormal my Elevated blood pressure   Loose stools  Strange oral outbreak of boil in back and top of mouth  and throat  General listlessness  Delayed memory recall
inadvertently administer  the vaccine 11 days after expiration date; The expired vial was stored in the refrigerator on 27may2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (inadvertently administer  the vaccine 11 days after expiration date) and PRODUCT STORAGE ERROR (The expired vial was stored in the refrigerator on 27may2022) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033K21-2A, 102M20A and 013A21a) for COVID-19 prophylaxis.     The patient had no known allergies.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-May-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-May-2022, the patient experienced PRODUCT STORAGE ERROR (The expired vial was stored in the refrigerator on 27may2022). On 31-May-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (inadvertently administer  the vaccine 11 days after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (inadvertently administer  the vaccine 11 days after expiration date) and PRODUCT STORAGE ERROR (The expired vial was stored in the refrigerator on 27may2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported.  The patient's height was reported as 6 foot 2 inches. It was unknown whether the patient ever had been diagnosed with/ tested positive for COVID 19. Acute and Chronic illness at the time of vaccination was reported as none.  On 31-May-2022, patient was administered with first booster dose. Number of doses/vials administered were reported as one vial. The vial had not undergone any temperature excursions.  No treatment medication were reported.
This spontaneous report was received from a nurse regarding a 9 week old male patient. The patient's pertinent medical history included eczema. The patient did not have any concomitant medications nor drug reactions or allergies. On 16-MAY-2016, the patient was vaccinated with a dose of ROTARIX (lot A41FB541A, expiration date 26-FEB-2017, dose and route of administration were not reported). Then the patient was sent to a second clinic to receive additional vaccines that the nurse's clinic did not have in stock. The patient's father told the second clinic that the patient had not received any vaccines at the previous clinic, and the patient was inadvertently administered a second dose of an unspecified rotavirus vaccine (orally, dose and lot # were not reported). The reporter was uncertain whether the second dose of rotavirus vaccine was ROTARIX or ROTATEQ. On the same day, the patient experienced diarrhea (the patient's father called nurse's clinic to inform about the adverse event). The patient did not receive any treatment and there was no lab diagnostics and studies performed. The patient's outcome was reported as not recovered/not resolved. The relatedness between the event of diarrhea and suspect therapies was not provided. Additional information has been requested.
The pt was given Menveo without reconstituting the vaccine. He was given the CWY only.  No adverse reactions reported to just giving Manufacturer said he does not need to be revaccinated unless he is going out of town were Men A is a common disease. MD and parent made aware.
On Sep 1 2009 pt received Inactivated INFLUENZA on left deltoid IM. Pt came 9/16/09 and stated she still had a dull pain, or soreness in her arm. There is no redness, itching or swelling at the injection site, asked pt to go to MD. office.
From initial information received on 12/20/04 from a physician regarding an adverse event occurring in the USA, it was reported that an approximately 50 year old male patient received MENOMUNE A/C/Y/W-135, sometime in November 2004 (exact date was not reported). The route and site of administration were not reported and the physician reported that the lot number information was not documented. Four to five days after receiving the vaccine, the patient developed an exacerbation of multiple sclerosis. The reporting physician did not have the patient information at the time of this report, but reportedly will be able to access it at a later date. It was not reported whether the patient recovered from this event. (OMIC)
This serious literature case, initially received on 12-Nov-2018 (combinedly processed), reported by other health professional and concerns a 42-year-old, adult, female patient. The patient had no historical condition. The patient's vaccination history included unspecified flu vaccine for an unknown indication and denied experiencing similar symptoms in the past. The patient did not use any medication including oral contraceptives and denied use of stimulants and caffeine supplements, including tea and coffee. On an unspecified date, the patient was administered Influenza virus vaccine (dose, route of administration, anatomical location, batch number, trade name, manufacturer and expiry date: not reported). On an unspecified period after vaccination, the patient had a post-vaccination prolonged viral-like illness. On an unspecified date, 3 weeks after vaccination, the patient presented with 2 weeks history of black-spot which turned green in the right eye. The patient also described the presence of paracentral scotoma. The patient denied any flashes, pain or blurred vision. On unspecified dates, the patient underwent Snellen vision acuity (VA) test which showed 20/20 with an intraocular pressure (IOP) of 12 mm Hg in the right eye and slit-lamp examination was unremarkable. Funduscopic examination revealed a slight reddish-brown petaloid lesion superonasal to the fovea. Near-infrared (SLO) imaging of the right eye revealed a wedge-shaped dark lesion superonasal to the fovea. Spectral-domain optical coherence tomography (SD-OCT) demonstrated hyperreflectivity of the outer plexiform layer (OPL), with characteristic shadowing of the ellipsoid zone. A fluorescein angiography was performed, but the findings were unremarkable and did not show signs of any other inflammatory lesions. The patient was diagnosed with acute macular neuroretinopathy (AMN) of the right eye likely secondary to the influenza vaccination and was observed for 4 weeks. On follow-up visit, 1 month later, the patient was experiencing a floater in the right eye but the improvement of the scotoma (recovering). The patient continued to deny any flashes, pain, or decline in vision. The VA in the right eye improved to 20/15 with an IOP of 19 mm Hg. Funduscopic exam no longer demonstrated a lesion. Near-infrared imaging showed interval improvement of the wedge-shaped lesion. SD-OCT showed improved hyperreflectivity of the OPL with decreased shadowing of the ellipsoid zone. At the time of this report, the patient was recovering from AMN and paracentral scotoma. The outcome of the events viral-like illness, floaters in the right eye and spots in the right eye was not reported. The reporter assessed the causality of the event AMN as related to the suspect vaccine (possibility of the influenza vaccination).
sore arm; This is a spontaneous report from a contactable Physician. A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and expiry date unknown) via unspecified route of administration on unspecified date at single dose for Covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced sore arm on unspecified date. The outcome of the event sore arm was unknown.  Follow-up activities are possible, information on the batch number has been requested.
This spontaneous report was received from an office manager refers to an unspecified number of patients of unknown demographics. On an unknown date the patients were vaccinated with RECOMBIVAX HB (lot#, expiration date and route not reported) that underwent unsupported temperature excursions and no adverse effects reports. No adverse effects reported. This is one of several reports from the same source. Additional information has been requested.
Information has been received from a physician's assistant concerning a 21 year old female patient who on 15-APR-2010 was vaccinated with the first dose of GARDASIL. On 15-APR-2010 the patient had an allergic reaction.  She got a rash around injection site. The patient had a red rash on the neck and arms. Also it was red and really dry around the eyes. She also had swelling in the upper eyelid. The patient sought unspecified medical attention. She was given a "MEDRAL" pack. At the time of the report, the patient was recovering. On 30-APR-2010, therapy with GARDASIL was discontinued. Additional information has been requested.
The inside of my mouth itched; Chin was swollen and hard to the touch; Lower lip itched; Lower lip swollen; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 03Apr2021 at 09:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to eggplant and the patient had no other relevant medical history. The patient had not received any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications or vaccines within 4 weeks prior to the vaccination. On 09Apr2021 at 17:00, a week after the injection, the patient experienced itching inside her mouth, the chin was swollen and hard to the touch and her lower lip itched on the inside and was swollen. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events itching inside mouth, chin swollen and hard to the touch, lower lip itched and swollen were resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected
Patient reports that approx. two wks after dose 1, an increase in auditory hallucinations with greater conviction occurred.  These were severe enough to warrant initiation of paliperidone on 05/27/21 as needed for breakthrough symptoms.  Patient reports symptoms have subsided somewhat.   Patient has formal diagnoses of Schizophrenia and Mild Mental Retardation.
Vaccinating RN removed 1/2 J+J dose from one vial and remainder from another vial. Same LOT #'s. No reaction from patient.
Within about 24 hours of receiving the shot, I presented with a blistering headache. The headache continued into Thursday. As Thursday proceeded swelling occurred and a rash appeared beneath the shot area of my arm. I believe it is called Covid arm. I used My Chart to contact the Doctor on March 12th at 3:11 p.m. but did not receive a response till the next week March 15th at 3:11 p.m.  As time passed the swelling and rash began to subside. However, it took at least over 5 -7 days for arm symptoms to subside.
Your vaccine has caused me stage 3 heart failure, myocarditis, Cardiomyopathy and now a rhythm issue, along with a heart attack at 40 years old. You gave me a death sentence.; Your vaccine has caused me stage 3 heart failure, myocarditis, Cardiomyopathy and now a rhythm issue, along with a heart attack at 40 years old. You gave me a death sentence.; Your vaccine has caused me stage 3 heart failure, myocarditis, Cardiomyopathy and now a rhythm issue, along with a heart attack at 40 years old. You gave me a death sentence.; Your vaccine has caused me stage 3 heart failure, myocarditis, Cardiomyopathy and now a rhythm issue, along with a heart attack at 40 years old. You gave me a death sentence.; heart attack at 40 years old; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old patient received bnt162b2 (BNT162B2 NOS), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: CARDIAC FAILURE (hospitalization, life threatening), MYOCARDITIS (hospitalization, life threatening), CARDIOMYOPATHY (hospitalization, life threatening), ARRHYTHMIA (hospitalization, life threatening), outcome "unknown" and all described as "Your vaccine has caused me stage 3 heart failure, myocarditis, Cardiomyopathy and now a rhythm issue, along with a heart attack at 40 years old. You gave me a death sentence."; MYOCARDIAL INFARCTION (hospitalization, life threatening), outcome "unknown", described as "heart attack at 40 years old". Clinical course: Could not even work now and had been in and out of hospital for over 2 years now. Never had a heart issue in life until second covid vaccine.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.
5-6 hours after vaccine sever chronic vomiting, weakness, confusion began.  Dry heaving or retching continued for the next 4-5-6 hours.  Sweating and chills along with extreme sever stomach pain continued until morning.  Went to Er and had tests done. Was told that appendix was needing removal and it was done. Vaccine was Moderna labeled lot 939905.  Maybe this was a coincidence or maybe not, but since the appendix has recently been linked to the immune system as possibly part of it purpose for existence it seemed prudent to make this report.
Pt developed fever 24hr after second dose. 2 days after second dose pt began experiencing chest pressure lasting 1 hour. Chest pressure reappeared at 03:00 6/14/21 with jaw pain. Ibuprofen made sxs worse.
Flu symptoms:  Muscle ache, achy joints, skin sensitivity, headache.  Very Sleepy.  Duration approximately 36-40 Hours.
A few days after shot patient had arm pain.  It progressed to shoulder impingement.  She started PT to help resolve the issue. Still has pain and limited mobility of arm.
pt recvd vax;25oct; inc t;to md; MD sent home;25oct late pm, pt to er w/ inc t; 26oct adm to hosp; Md thinks may be roseola or viral; presently inc WBC, inc t, urinalysis, spinal tap, chest x-ray all neg;
I noticed red, itchy patches on my left forearm, a few spots on my right forearm. I also have a itchy, swollen spot on my left t; swollen spot on my left; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 45-years-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported, Expiry date was not reported) via an unspecified route of administration, administered in Arm Left on 18Apr2021 09:30 (at the age of 45 years old) as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history included I have ibs but nothing else I'm aware of. The patient have sensitives to augmentin [amoxicillin;clavulanic acid](previously took), bananas, some dairy products. Concomitant medication(s) included ascorbic acid, ergocalciferol, folic acid, nicotinamide, panthenol, retinol, riboflavin, thiamine hydrochloride (MULTIVITAMINS [ASCORBIC ACID; ERGOCALCIFEROL; FOLIC ACID;NICOTINAMIDE;PANTHENOL;RETINOL;RIBOFLAVIN;THIAMINE HYDROCHLORIDE]) taken for an unspecified indication, start and stop date were not reported, non drowsy allergy relief, nasal sp. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported, Expiry date was not reported) via an unspecified route of administration, administered in Arm Left on 26Mar2021 05:15 (age at vaccination 45 years) as DOSE 1, SINGLE for covid-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient had not received any other vaccine within 4 weeks. The patient received, Multi vitamin, non-drowsy allergy relief, nasal sp as other medications in two weeks. The reporter states, on 18Apr2021 17:00. I noticed red, itchy patches on my left forearm, a few spots on my right forearm. I also have a itchy, swollen spot on my left. Treatment was unknown. The patient underwent lab tests and procedures which included sars-cov-2 test unknown on 18Apr2021 Nasal Swab. The outcome for the events was recovering.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained. No further information is expected.
No adverse Event. Reporting according the the FDA Recommendations, that we are no longer giving monovalent
Patient arrived in ER with complaint of several months of headaches, double vision, dizziness and .  No surgical intervention was needed.  Patient started on 3% sodium chloride (hypertonic solution).
penis is swollen; injection site reaction; This spontaneous case was reported by a consumer and describes the occurrence of PENILE SWELLING (penis is swollen) and VACCINATION SITE REACTION (injection site reaction) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jul-2021, the patient experienced PENILE SWELLING (penis is swollen) and VACCINATION SITE REACTION (injection site reaction). At the time of the report, PENILE SWELLING (penis is swollen) and VACCINATION SITE REACTION (injection site reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products were not provided/unknown.  Treatment medication were not reported/unknown.
This spontaneous report as received from a registered nurse refers to an unknown number of patients of unknown age and gender. No relevant medical history or concurrent conditions were reported. On unknown dates, the patients were vaccinated with improperly stored GARDASIL (dose, route, lot# and expiration date were not reported; therapy type: digital data logger). Temperature excursion information was reported as: below 36 Fahrenheit, more than 25 times (unknown by the reporter). No adverse effects were reported. This is one of several reports received from the same reported. Additional information has been requested.